Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome
Open accessAbstract
Background Conventional therapies for hypereosinophilic syndromes (HES) have variable efficacy and carry significant long-term toxicities. Anti-IL-5 (mepolizumab) therapy has a glucocorticoid (GC)-sparing effect in GC-sensitive HES, but the efficacy of mepolizumab in treatment-refractory HES patients with severe disease has not been examined to date.Objective To identify predictors of response to mepolizumab in subjects with severe treatment-refractory HES and compare long-term outcomes in these subjects with HES subjects treated with conventional therapies.Methods Retrospective analysis of clinical and laboratory data from 35 HES subjects treated with mepolizumab and 55 HES subjects on conventional therapy, all followed at a single center, was performed.Results Peak eosinophilia, GC sensitivity, pulmonary involvement, HES clinical subtype, and pretreatment serum IL-5 were correlated with mepolizumab response. Despite evidence of more severe disease at baseline, mepolizumab-treated subjects had comparable long-term clinical outcomes to HES subjects treated with conventional therapies and reported improvements in therapy-related comorbidities. Subjects managed with mepolizumab monotherapy had fewer disease flares than HES subjects on conventional therapies or mepolizumab-treated HES subjects requiring additional HES therapies.Conclusions This study confirms that mepolizumab is an effective and well-tolerated therapy for HES, but suggests that response is more likely in GC-responsive subjects with idiopathic or overlap forms of HES. A primary benefit of treatment is the reduction of comorbidity due to discontinuation or the reduction of conventional HES therapies. Although subjects who completely discontinued GC had the most benefit, high-dose mepolizumab was a safe and effective salvage therapy for severe, treatment-refractory HES.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mepolizumab was efficient and safe in treatment-refractory hypereosinophilic syndrome patients with severe disease.
“and mepolizumab was efficient and safe in treatment-refractory HES patients with severe disease.130”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Multiple Comparison Procedures
Hochberg, Y., & Tamhane, A. C. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316672 · Cited by 2,389 · see citing works
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G., FitzGerald, J. M., Chetta, A. A., Humbert, M. J. C., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,320 · see citing works
Self-citationPavord, I. D., Korn, S., Howarth, P. H., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H. G., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221 · see citing works
Self-citationMultiple Comparison Procedures
Hahs-Vaughn, D., & Lomax, R. (2013) · Routledge eBooks · doi:10.4324/9780203137819-17 · Cited by 2,132 · see citing works
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W. R., Sousa, A. R., Marshall, R. P., Bradding, P. H., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,862 · see citing works
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P. K., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O’Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,346 · see citing works
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Wechsler, M. E., Akuthota, P., Jayne, D. G., Khoury, P., Klion, A. D., Langford, C. A., Merkel, P. A., Moosig, F., Specks, U., Cid, M. C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702079 · Cited by 1,091 · see citing works
Self-citationMepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease
Pavord, I. D., Chanez, P., Criner, G. J., Kerstjens, H. A. M., Korn, S., Lugogo, N. L., Martinot, J., Sagara, H., Albers, F. C., Bradford, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708208 · Cited by 628 · see citing works
Ogbogu, P. U., Bochner, B. S., Butterfield, J. H., Gleich, G. J., Huss‐Marp, J., Kahn, J., Leiferman, K. M., Nutman, T. B., Pfab, F., Ring, J., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.022 · Cited by 625 · see citing works
Self-citationTreatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
Rothenberg, M. E., Klion, A. D., Roufosse, F. E., Kahn, J., Weller, P. F., Simon, H., Schwartz, L. B., Rosenwasser, L. J., Ring, J., Griffin, E. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa070812 · Cited by 583 · see citing works
Self-citationBartemes, K. R., Iijima, K., Kobayashi, T., Kephart, G. M., McKenzie, A. N., & Kita, H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102832 · Cited by 549 · see citing works
Anti–IL-5 (mepolizumab) therapy for eosinophilic esophagitis
Stein, M., Collins, M. H., Villanueva, J. M., Kushner, J. P., Putnam, P. E., Buckmeier, B. K., Filipovich, A. H., Assa’ad, A., & Rothenberg, M. E. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.09.007 · Cited by 459 · see citing works
Anti–interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes
Garrett, J. K., Jameson, S. C., Thomson, B. G., Collins, M. H., Wagoner, L. E., Freese, D. K., Beck, L. A., Boyce, J. A., Filipovich, A. H., Villanueva, J. M., et al. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.10.049 · Cited by 362 · see citing works
Clonal Proliferation of Type 2 Helper T Cells in a Man with the Hypereosinophilic Syndrome
Cogan, E., Schandené, L., Crusiaux, A., Cochaux, P., Velu, T. J., & Goldman, M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199402243300804 · Cited by 305 · see citing works
How I treat hypereosinophilic syndromes
Klion, A. D. (2015) · Blood · doi:10.1182/blood-2014-11-551614 · Cited by 296 · see citing works
Self-citationMepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
Kim, S., Marigowda, G., Oren, E., Israel, E., & Wechsler, M. E. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.03.028 · Cited by 280 · see citing works
Use of an Anti–Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic Dermatitis
Plötz, S. G., Simon, H., Darsow, U. G., Simon, D., Vassina, E. M., Yousefi, S., Hein, R., Smith, T., Behrendt, H., & Ring, J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031261 · Cited by 257 · see citing works
Targeting Interleukin-5 in Refractory and Relapsing Churg–Strauss Syndrome
Moosig, F., Gross, W. L., Herrmann, K., Bremer, J. P., & Hellmich, B. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-5-201109060-00026 · Cited by 205 · see citing works
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes
Roufosse, F. E., Kahn, J., Gleich, G. J., Schwartz, L. B., Singh, A. D., Rosenwasser, L. J., Denburg, J. A., Ring, J., Rothenberg, M. E., Sheikh, J. K., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.055 · Cited by 176 · see citing works
Self-citationKlion, A. D., Law, M. A., Noël, P., Kim, Y., Haverty, T. P., & Nutman, T. B. (2003) · Blood · doi:10.1182/blood-2003-10-3620 · Cited by 162 · see citing works
Self-citationMepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome
Roufosse, F. E., de Lavareille, A., Schandené, L., Cogan, E., Georgelas, A., Wagner, L. A., Xi, L., Raffeld, M. A., Goldman, M., Gleich, G. J., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.06.049 · Cited by 113 · see citing works
Self-citationHypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids
Khoury, P., Abiodun, A. O., Holland-Thomas, N. C., Fay, M. P., & Klion, A. D. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.06.006 · Cited by 70 · see citing works
Self-citationAnalysis of the Glycan Composition on Plasma Derived ADAMTS13 Employing Tandem Mass Spectrometry
Verbij, F. C., Stokhuijzen, E., van Alphen, F. P. J., Kaijen, P. H. P., Meijer, A. B., & Voorberg, J. (2015) · Blood · doi:10.1182/blood.v126.23.1069.1069 · Cited by 63 · see citing works
Bochner, B. S., Book, W., Busse, W. W., Butterfield, J. H., Furuta, G. T., Gleich, G. J., Klion, A. D., Lee, J. J., Leiferman, K. M., Minnicozzi, M., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.024 · Cited by 55 · see citing works
Self-citationKhoury, P., Desmond, R. G., Pabon, A., Holland-Thomas, N. C., Ware, J. M., Arthur, D., Kurlander, R. J., Fay, M. P., Maric, I., & Klion, A. D. (2016) · Allergy · doi:10.1111/all.12843 · Cited by 55 · see citing works
Self-citationClinical and Biological Markers in Hypereosinophilic Syndromes
Khoury, P., Makiya, M. A., & Klion, A. D. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00240 · Cited by 35 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- [14]Duncan EA, Ortega H, Gleich G, Price R, Yancey S, Klion AD. Observational experience describing the use of mepolizumab in patients with hypereosinophilic syndrome. Am J Respir Crit Care Med 2015; 191: A1365.
Cited by
Sorted by citations
A new dawn for eosinophils in the tumour microenvironment
Grisaru‐Tal, S., Itan, M., Klion, A. D., & Munitz, A. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0283-9 · Cited by 306 · see citing works
Self-citationContributions of Eosinophils to Human Health and Disease
Klion, A. D., Ackerman, S. J., & Bochner, B. S. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032756 · Cited by 246 · see citing works
Self-citationBenralizumab for PDGFRA -Negative Hypereosinophilic Syndrome
Kuang, F. L., Legrand, F., Makiya, M. A., Ware, J. M., Wetzler, L., Brown, T., Magee, T., Piligian, B., Yoon, P., Ellis, J. H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812185 · Cited by 223 · see citing works
Self-citationHaanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222 · see citing works
Shomali, W. E., & Gotlib, J. R. (2019) · American Journal of Hematology · doi:10.1002/ajh.25617 · Cited by 190 · see citing works
Shomali, W. E., & Gotlib, J. R. (2021) · American Journal of Hematology · doi:10.1002/ajh.26352 · Cited by 183 · see citing works
Jacobsen, E. A., Jackson, D. J., Heffler, E. M., Mathur, S. K., Bredenoord, A. J., Pavord, I. D., Akuthota, P., Roufosse, F. E., & Rothenberg, M. E. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-093019-125918 · Cited by 136 · see citing works
Shomali, W. E., & Gotlib, J. R. (2024) · American Journal of Hematology · doi:10.1002/ajh.27287 · Cited by 122 · see citing works
From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases
Pavord, I. D., Bel, E. H., BOURDIN, A. A., Chan, R. H., Han, J. K., Keene, O. N., Liu, M. C., Martin, N., Papi, A. A., Roufosse, F. E., et al. (2021) · Allergy · doi:10.1111/all.15056 · Cited by 116 · see citing works
Self-citationEosinophils and eosinophilic immune dysfunction in health and disease
Jackson, D. J., Akuthota, P., & Roufosse, F. E. (2022) · European Respiratory Review · doi:10.1183/16000617.0150-2021 · Cited by 112 · see citing works
Approach to Patients with Eosinophilia
Kuang, F. L. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2019.08.005 · Cited by 74 · see citing works
Self-citationApproach to the patient with suspected hypereosinophilic syndrome
Klion, A. D. (2022) · Hematology · doi:10.1182/hematology.2022000367 · Cited by 70 · see citing works
Self-citationHypereosinophilic syndrome: approach to treatment in the era of precision medicine
Klion, A. D. (2018) · Hematology · doi:10.1182/asheducation-2018.1.326 · Cited by 62 · see citing works
Self-citationFaverio, P., Bonaiti, G., Bini, F., Vaghi, A., & Pesci, A. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s159949 · Cited by 51 · see citing works
Pediatric Hypereosinophilia: Characteristics, Clinical Manifestations, and Diagnoses
Burris, D. L., Rosenberg, C. E., Schwartz, J. T., Zhang, Y., Eby, M. D., Abonia, J. P., & Fulkerson, P. C. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.05.011 · Cited by 49 · see citing works
Carpentier, C., Verbanck, S., Schandené, L., Heimann, P., Trépant, A., Cogan, E., & Roufosse, F. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01765 · Cited by 49 · see citing works
Prominent Role of Type 2 Immunity in Skin Diseases: Beyond Atopic Dermatitis
Belmesk, L., Muntyanu, A., Cantin, E., Alhalees, Z., Jack, C. S., Le, M., Sasseville, D., Iannattone, L., Ben‐Shoshan, M., Litvinov, I. V., et al. (2021) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/12034754211027858 · Cited by 49 · see citing works
Helbig, G., & Klion, A. D. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100809 · Cited by 41 · see citing works
Self-citationChen, M. M., Roufosse, F. E., Wang, S. A., Verstovšek, S., Durrani, S. R., Rothenberg, M. E., Pongdee, T., Butterfield, J. H., Lax, T. P., Wechsler, M. E., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.02.006 · Cited by 41 · see citing works
Self-citationSoeda, S., To, M., Kono, Y., Yamawaki, S., Tsuzuki, R., Katsube, O., Watanabe, N., & To, Y. (2019) · Allergology International · doi:10.1016/j.alit.2018.12.008 · Cited by 38 · see citing works
Khoury, P., & Bochner, B. S. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.04.030 · Cited by 31 · see citing works
Self-citationCritical Points on the Use of Biologicals in Allergic Diseases and Asthma
Agache, I. O., Cojanu, C., Laculiceanu, A. G., & Rogozea, L. M. (2019) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2020.12.1.24 · Cited by 28 · see citing works
Early benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis
Colantuono, S., Pellicano, C., Leodori, G., Cilia, F., Francone, M., & Visentini, M. (2020) · Allergology International · doi:10.1016/j.alit.2020.03.001 · Cited by 27 · see citing works
Approach to Eosinophilia Presenting With Pulmonary Symptoms
Rosenberg, C. E., & Khoury, P. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.09.247 · Cited by 27 · see citing works
Self-citationKoga, Y., Aoki‐Saito, H., Kamide, Y., Sato, M., Tsurumaki, H., Yatomi, M., Ishizuka, T., & Hisada, T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.865318 · Cited by 26 · see citing works
Gotlib, J. R. (2022) · Hematology · doi:10.1182/hematology.2022000368 · Cited by 26 · see citing works
Iurlo, A., Cattaneo, D., & Gianelli, U. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1677461 · Cited by 25 · see citing works
Caminati, M., Brussino, L., Carlucci, M., Carlucci, P., Carpagnano, L. F., Caruso, C., Cosmi, L., D’Amore, S., Giacco, S. D., Detoraki, A., et al. (2024) · Cells · doi:10.3390/cells13141180 · Cited by 24 · see citing works
Rothenberg, M. E., Roufosse, F. E., Faguer, S., Gleich, G. J., Steinfeld, J., Yancey, S. W., Mavropoulou, E., Kwon, N., García, G. R., Sosso, A., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.04.037 · Cited by 24 · see citing works
Self-citationRecent advances in understanding the role of eosinophils
Constantine, G. M., & Klion, A. D. (2022) · Faculty Reviews · doi:10.12703/r/11-26 · Cited by 23 · see citing works
Self-citationTherapeutic strategies for eosinophilic dermatoses
Simon, D., & Simon, H. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.01.002 · Cited by 22 · see citing works
Shabbir, S. S., Pouliquen, I. J., Bentley, J. H., Bradford, E., Kaisermann, M. C., & Albayaty, M. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.726 · Cited by 21 · see citing works
Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies
Kuang, F. L., Khoury, P., Weller, P. F., Wechsler, M. E., & Klion, A. D. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.07.026 · Cited by 21 · see citing works
Self-citationWilliams, A. K., Dou, C., & Chen, L. Y. C. (2021) · British Journal of Haematology · doi:10.1111/bjh.17615 · Cited by 19 · see citing works
The efficacy of off-label IL-5-modulating treatment in rare eosinophil-mediated diseases
Shamriz, O., Hershko, A. Y., Talmon, A., Ribak, Y., Elazary, A. S., Horev, L., NaserEddin, A., Neuman, T., Shabat, S., Zlotogorski, A., et al. (2020) · Allergology International · doi:10.1016/j.alit.2020.10.001 · Cited by 18 · see citing works
Dellon, E. S., Simon, D., & Wechsler, M. E. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.01.043 · Cited by 18 · see citing works
Lessons learned from targeting eosinophils in human disease
Kuang, F. L., & Bochner, B. S. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00849-w · Cited by 14 · see citing works
Self-citationMechanisms of glucocorticoid resistance in hypereosinophilic syndromes
Stokes, K., Yoon, P., Makiya, M. A., Gebreegziabher, M. B., Holland-Thomas, N. C., Ware, J. M., Wetzler, L., Khoury, P., & Klion, A. D. (2019) · Clinical & Experimental Allergy · doi:10.1111/cea.13509 · Cited by 13 · see citing works
Self-citationEosinophil-associated diseases: the allergist's and clinical immunologist's perspective
Marra, A. M., Rossi, C. M., Piga, M. A., Moroncini, G., & Bilò, M. B. (2024) · European Annals of Allergy and Clinical Immunology · doi:10.23822/eurannaci.1764-1489.339 · Cited by 12 · see citing works
Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis
Nguyen, L., Saha, A., Kuykendall, A. T., & Zhang, L. (2024) · Cancers · doi:10.3390/cancers16071383 · Cited by 12 · see citing works
Rubin, L., Talmon, A., Ribak, Y., Lavie, D., Nechushtan, H., Caplan, N., Lotem, M., Shamriz, O., Adini, I., & Tal, Y. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009658 · Cited by 12 · see citing works
Repurposing of Chemotherapeutics to Combat COVID-19
Nandi, S., Nayak, B. S., Khede, M. K., & Saxena, A. K. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666221130142517 · Cited by 11 · see citing works
The Journal of Allergy and Clinical Immunology: In Practice 2018 Highlights
Schatz, M. X., Sicherer, S. H., Khan, D. A., & Zeiger, R. S. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.12.007 · Cited by 11 · see citing works
Khoury, P., Makiya, M. A., Rahim, R., Bowman, A., Espinoza, D., Schiffenbauer, A. I., Koch, M., Anderson, C., Constantine, G. M., Marić, I., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.11.002 · Cited by 10 · see citing works
Self-citationBaulier, G., Asli, B., Galicier, L., Fieschi, C., Brice, P., & Malphettes, M. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.04.039 · Cited by 10 · see citing works
Kuang, F. L., Makiya, M. A., Ware, J. M., Wetzler, L., Nelson, C. M., Brown, T., Khoury, P., & Klion, A. D. (2025) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2025.03.016 · Cited by 9 · see citing works
Self-citationKodaka, N., Nakano, C., Oshio, T., Hirouchi, T., Satou, M., Moroi, M., Oharaseki, T., & Matsuse, H. (2021) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14329 · Cited by 9 · see citing works
Eosinophils: A Friend or Foe in Human Health and Diseases
Syeda, M. Z., Tu, H., Zhang, C., Ying, S., & Shen, H. (2022) · Kidney Diseases · doi:10.1159/000528156 · Cited by 9 · see citing works
Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis
Junior, J. M. A., Prota, F. E., Villagelin, D., Bley, F., & Bernardo, W. M. (2021) · Clinics · doi:10.6061/clinics/2021/e3271 · Cited by 8 · see citing works
Iurlo, A., & Cattaneo, D. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101014 · Cited by 8 · see citing works
Munari, S., Ciotti, G., Cestaro, W., Corsi, L., Tonin, S., Ballarin, A., Floriani, A., Dartora, C., Bosi, A., Tacconi, M., et al. (2024) · Drugs in Context · doi:10.7573/dic.2024-3-5 · Cited by 8 · see citing works
Hypereosinophilia causes progressive cardiac pathologies in mice
Diny, N. L., Wood, M. K., Won, T., Talor, M. V., Lukban, C., Bedja, D., Wang, N., Kalinoski, H., Daoud, A., Talbot, C. C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107990 · Cited by 7 · see citing works
Hwee, J., Huynh, L. Y., Pongdee, T., Rothenberg, M. E., Alfonso-Cristancho, R., da Costa, W., & Duh, M. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124309 · Cited by 7 · see citing works
Hypereosinophilic syndrome response to mepolizumab in the setting of a compassionate use program
Coussement, G., Catherine, J., & Roufosse, F. E. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae152 · Cited by 7 · see citing works
Severe asthma with blood hypereosinophilia associated withJAK2V617F mutation: a case series
Tabèze, L., Marchand-Adam, S., Borie, R., Justet, A., Dupin, C., Dombret, M.-C., Crestani, B., & Taillé, C. (2019) · European Respiratory Journal · doi:10.1183/13993003.02248-2018 · Cited by 7 · see citing works
Clinical Management of Persistent Hypereosinophilia
Helbig, G., & Czachor, K. (2025) · European Journal Of Haematology · doi:10.1111/ejh.14396 · Cited by 6 · see citing works
Hypereosinophilic syndrome with central nervous system involvement treated with anti-IL-5 therapy
Jonakowski, M., Kuprys-Lipinska, I. R., Łacwik, P., Stasiołek, M., & Matysiak, M. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102871 · Cited by 6 · see citing works
Ledoult, E., Groh, M., Meresse, B., Dubois, R., Trauet, J., Toussaint, E., Delbeke, M., HACHULLA, E., Terriou, L., de Masson, A., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284429 · Cited by 6 · see citing works
Catherine, J., Karimi, S., Dewispelaere, L., Lelubre, C., Schandené, L., & Roufosse, F. E. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.12.1085 · Cited by 6 · see citing works
Lazzari, C., Yacoub, M., Campochiaro, C., Bulotta, A., Palumbo, D., Ogliari, F. R., Dagna, L., Marchesi, S., Ponzoni, M., & Gregorc, V. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1079034 · Cited by 6 · see citing works
Khoury, P., Roufosse, F. E., Kuang, F. L., Ackerman, S. J., Akuthota, P., Bochner, B. S., Johansson, M. W., Mathur, S. K., Ogbogu, P. U., Spencer, L. A., et al. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae051 · Cited by 6 · see citing works
Self-citationHypereosinophilia with angioimmunoblastic T-cell lymphoma
Eng, V., Kulkarni, S. K., Kaplan, M., Samant, S. A., & Sheikh, J. K. (2020) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2020.01.028 · Cited by 5 · see citing works
INTERLEUKIN-5 IS A NEW TARGET IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Beketova, T. V., & Arseniev, E. V. (2020) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2020-321-329 · Cited by 5 · see citing works
Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
Otoshi, R., Baba, T., Komatsu, S., Asaoka, M., Hagiwara, E., & Ogura, T. (2019) · Respirology Case Reports · doi:10.1002/rcr2.514 · Cited by 5 · see citing works
Steroid alternatives for managing eosinophilic lung diseases
Delcros, Q., Groh, M., Nasser, M., Kahn, J., & Cottin, V. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.2003777 · Cited by 5 · see citing works
Safety of eosinophil depletion
Jackson, D. J., & Munitz, A. (2022) · European Respiratory Society eBooks · doi:10.1183/2312508x.10030820 · Cited by 4 · see citing works
Phase II trial of imatinib mesylate in patients with PDGFRA/B ‐negative hypereosinophilic syndrome
Kim, D. H., Kim, S., Park, S., Byun, J. M., Hong, J., Shin, D., Kim, I., Bang, S., Lee, J., Lee, J. Y., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19828 · Cited by 4 · see citing works
Improving patient outcomes: Mepolizumab’s impact in IL-5-mediated diseases
Gothi, D., Narasimhan, R., Guleria, R., Chopra, M., Gvalani, A., & Hegde, R. (2025) · Lung India · doi:10.4103/lungindia.lungindia_442_24 · Cited by 3 · see citing works
An introduction to eosinophils and their biology
Ackerman, S. J. (2022) · European Respiratory Society eBooks · doi:10.1183/2312508x.10029020 · Cited by 3 · see citing works
Idiopathic hypereosinophilic syndrome presenting as cardiac tamponade and multiorgan dysfunction
Roth, K. M., Gupta, S., Paul, V., & Patel, P. P. (2023) · BMJ Case Reports · doi:10.1136/bcr-2023-256274 · Cited by 3 · see citing works
Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis
Ezekwe, E., Weskamp, A. L., Pittman, L. M., & Klion, A. D. (2024) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2024.07.003 · Cited by 3 · see citing works
Self-citationChronic Eosinophilic Leukemia: Diagnosis and Therapy
Gotlib, J. R., Shomali, W. E., & Reiter, A. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(21)01197-6 · Cited by 3 · see citing works
Cottin, V. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_17 · Cited by 3 · see citing works
Eosinophils and the Scope of Practice in Allergy/Immunology
Kelly, K. J. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.07.016 · Cited by 3 · see citing works
Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence
Mora, E., Fox, M. L., Lemes, A., Velasco, B., & Hernández‐Rivas, J. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1704077 · Cited by 2 · see citing works
Giordani, A. S., Menghi, C., Baritussio, A., Scognamiglio, F., Vicenzetto, C., Davanzo, F., Iorio, L., Marcolongo, R., Gaspari, M. D., Rizzo, S., et al. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag025 · Cited by 2 · see citing works
Familial clustering of hypereosinophilic diseases treated with mepolizumab: a case report from Japan
Kurosawa, M., SUTOH, Y., & Sutoh, E. (2019) · European Annals of Allergy and Clinical Immunology · doi:10.23822/eurannaci.1764-1489.112 · Cited by 2 · see citing works
The use of biologics in personalized asthma care
Watchorn, D., & Holguin, F. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.2006635 · Cited by 2 · see citing works
Development of a Patient-Reported Outcome Measure for Hypereosinophilic Syndrome
Khoury, P., Mahmood, S., Berry, A., Mata, D., Kimel, M., McCormack, J., Prussin, C., & Klion, A. D. (2025) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2025.09.008 · Cited by 2 · see citing works
Self-citationAl‐Shaikhly, T., Norris, M. R., Stern, H. H., & Ghaffari, G. (2022) · Springer eBooks · doi:10.1007/978-3-031-12867-7_12 · Cited by 2 · see citing works
Expansion of multiple CD4+ T-cell lineages in lymphocytic variant hypereosinophilic syndrome
Anderson, C. F., Makiya, M. A., Xiong, K., Penrod, L., Wetzler, L., Ware, J. M., Constantine, G. M., Khoury, P., & Klion, A. D. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.04.027 · Cited by 1 · see citing works
Self-citationHwee, J., Huynh, L. Y., da Costa, W., Rothenberg, M. E., Duh, M. S., & Alfonso‐Cristancho, R. (2025) · Frontiers in Allergy · doi:10.3389/falgy.2025.1605397 · Cited by 1 · see citing works
Advances in the treatment of eosinophilic granulomatosis with polyangiitis
Cottu, A., Roufosse, F. E., Egan, A. C., Emmi, G., Groh, M., Nanzer, A. M., Specks, U., Wechsler, M. E., Vaglio, A., & Terrier, B. (2026) · Nature Reviews Rheumatology · doi:10.1038/s41584-026-01406-1 · Cited by 1 · see citing works
Dexpramipexole: A Potential Non-biologic Alternative for Patients with Eosinophilic Asthma?
Kuang, F. L. (2022) · touchREVIEWS in Respiratory & Pulmonary Diseases · doi:10.17925/usrpd.2022.7.2.36 · Cited by 1 · see citing works
Self-citationMcBrien, C., & Menzies-Gow, A. N. (2019) · doi:10.1183/9781849840798.011618 · Cited by 1 · see citing works
Eosinophilia and the Hypereosinophilic Syndrome: Clinical, Molecular and Translational Aspects
Jackson, C., Sasankh, A. K., Arumugam, N. K., Raj, S., Ames, E., & Krishnaswamy, G. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00031-7
Fırat, A. A. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005630
Ma, S., Hu, Y., Liu, S., Wang, J., Zhang, K., Zhu, Y., & Wu, Y. (2025) · Next research. · doi:10.1016/j.nexres.2025.100525
Amer, J., Noori, F., Hamdan, D., Mokhaimar, T., & Salhab, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1595193
Askins, D. H., Bobo, E. W., Chacko, B. J., Mansourian, K. A., McDonough, S. R., Baptiste, C. J., Mathew, J. S., Klapper, V. G., Witt, A. S. D., Shekoohi, S., et al. (2025) · Advancements in health research. · doi:10.4081/ahr.2025.29
Jain, P., Rowell, J. V., Edmonds, C., Stokes, M., Ding, N., & Chen, S. Y. (2025) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2025.100608
Wang, Y., Tao, Y., & Mao, H. (2026) · Central European Journal of Immunology · doi:10.5114/ceji/213650
Chhiba, K. D., Kasjanski, R., Makiya, M. A., Brown, T., Khoury, P., Klion, A. D., & Kuang, F. L. (2026) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2026.100722
Self-citationBalykova, L. A., Krasnopolskaya, A. V., Vereshchagina, V. S., Васильевна, Ш. М., Pigacheva, O. Y., Stradina, A. A., & Ledyaykina, S. A. (2026) · Педиатрическая фармакология · doi:10.15690/pf.v23i2.3028
Chevalier, K., Barde, F., Faguer, S., Freymond, N., Lahmar, Z. M., BOURDIN, A. A., Canu, D., Néel, A., Grange, L., Taillé, C., et al. (2026) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2026.09.021
Cid, M. C., Hellmich, B., Terrier, B., Tian, X., Wechsler, M. E., Baylis, L., & Roufosse, F. E. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104207
- Authors
- Kuang, F. L., Fay, M. P., Ware, J., Wetzler, L., Holland-Thomas, N., Brown, T., Ortega, H., Steinfeld, J., Khoury, P., & Klion, A. D.
- Affiliations
- National Institutes of Health (US)
- Frederick National Laboratory for Cancer Research (US)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Kuang, Fei Li
- ORCID
- Venue
- The Journal of Allergy and Clinical Immunology In Practice
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 6
- Issue
- 5
- Pages
- 1518-1527.e5
- ISSN
- 2213-2198 (ISSN-L)
- PMC
- PMC6173586
- OpenAlex
- W2802833453
- Cited by
- 94
- References
- 26
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 13 · 2023: 6 · 2022: 15 · 2021: 13 · 2020: 9 · 2019: 15 · 2018: 5
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Allergy and Clinical Immunology In Practice (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (HHSN261200800001C, Z99 AI999999)
- National Cancer Institute (HHSN261200800001E))
- Topics
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- hypereosinophilic syndrome, mepolizumab, anti-IL-5 therapy, refractory disease, glucocorticoid sensitivity, predictors of treatment response, disease flares, pulmonary involvement, long-term clinical outcomes, comorbidity reduction, salvage therapy
- MeSH terms
- Adult, Aged, Drug Resistance, Eosinophils, Female, Follow-Up Studies, Glucocorticoids, Humans, Immunotherapy, Male, Middle Aged, Retrospective Studies, Time Factors, Interleukin-5, Treatment Outcome, Hypereosinophilic Syndrome, Disease Progression, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
